IMLFF News and Press, InMed Pharmaceuticals Inc. From 11/05/20

InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020 PR Newswire VANCOUVER, BC, Nov. 5, 2020 VANCOUVER, BC , Nov. 5, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OT...

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020 Canada NewsWire VANCOUVER, BC, Nov. 4, 2020 TSX:IN OTCQX:IMLFF VANCOUVER, BC , Nov. 4, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("...

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire VANCOUVER, BC, Sept. 24, 2020 VANCOUVER, BC , Sept. 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "...

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing Canada NewsWire VANCOUVER, BC, Sept. 22, 2020 TSX:IN OTCQX:IMLFF VANCOUVER, BC , Sept. 22, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (O...

InMed Pharmaceuticals Inc. (IMLFF) Q4 2020 Earnings Conference Call September 08, 2020 11:30 AM ET Company Participants Brendan Payne - Director, Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vi...

InMed Pharmaceuticals ( OTCQX:IMLFF ) : FY GAAP EPS of -C$2.27. Cash, cash equivalents and short-term of C$8M Press Release More news on: InMed Pharmaceuticals Inc., Earnings news and commentary, Tech stocks news, ,

VANCOUVER, BC , Sept. 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of can...

TSX:IN OTCQX:IMLFF   VANCOUVER, BC , Sept. 2, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

InMed Pharmaceuticals ( OTCQX:IMLFF ) initiates  patient dosing in its second Phase 1 clinical trial with INM-755 ("755-102-HV"). More news on: InMed Pharmaceuticals Inc., Healthcare stocks news, Read more ...

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755 Canada NewsWire VANCOUVER, BC, July 7, 2020 TSX:IN OTCQX:IMLFF VANCOUVER, BC , July 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage ...